Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Current Deferred Revenue (2016 - 2025)

BioCorRx's Current Deferred Revenue history spans 16 years, with the latest figure at $56590.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $56590.0; the TTM value through Sep 2025 reached $56590.0, changed N/A, while the annual FY2024 figure was $56590.0, 1299.01% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $56590.0 at BioCorRx, roughly flat from $56590.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $56590.0 in Q4 2024 and bottomed at $4045.0 in Q1 2023.
  • The 5-year median for Current Deferred Revenue is $34981.0 (2021), against an average of $29700.6.
  • The largest annual shift saw Current Deferred Revenue crashed 89.16% in 2023 before it surged 1299.01% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $34981.0 in 2021, then rose by 6.63% to $37301.0 in 2022, then plummeted by 89.16% to $4045.0 in 2023, then soared by 1299.01% to $56590.0 in 2024, then changed by 0.0% to $56590.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Current Deferred Revenue are $56590.0 (Q3 2025), $56590.0 (Q2 2025), and $56590.0 (Q4 2024).